HighTide Therapeutics Valuation
Is 2511 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2511 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2511's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2511's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2511?
Key metric: As 2511 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 2511's PB Ratio? | |
|---|---|
| PB Ratio | 0.9x |
| Book | CN¥548.66m |
| Market Cap | CN¥503.10m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 2511's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.8x | ||
2126 JW (Cayman) Therapeutics | 0.3x | -1.8% | HK$534.0m |
1244 3D Medicines | 0.5x | n/a | HK$482.7m |
9939 Kintor Pharmaceutical | 1.1x | 25.8% | HK$463.3m |
2898 Sunho Biologics | 1.2x | n/a | HK$696.1m |
2511 HighTide Therapeutics | 0.9x | n/a | HK$540.5m |
Price-To-Book vs Peers: 2511 is expensive based on its Price-To-Book Ratio (0.9x) compared to the peer average (0.8x).
Price to Book Ratio vs Industry
How does 2511's PB Ratio compare vs other companies in the HK Biotechs Industry?
Price-To-Book vs Industry: 2511 is good value based on its Price-To-Book Ratio (0.9x) compared to the Hong Kong Biotechs industry average (2.3x).
Price to Book Ratio vs Fair Ratio
What is 2511's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2511's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
3SBio
HK$13.0b
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
1530
HK$5.52
7D
-4.3%
1Y
-26.2%
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a
China Shineway Pharmaceutical Group
HK$6.1b
An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
2877
HK$8.13
7D
-3.3%
1Y
n/a